

MEDICAL POLICY

POLICY TITLE	LABORATORY AND GENETIC TESTING FOR USE OF 5-FLUOROURACIL IN PATIENTS WITH CANCER
POLICY NUMBER	MP 2.354

CLINICAL BENEFIT	<input type="checkbox"/> MINIMIZE SAFETY RISK OR CONCERN. <input checked="" type="checkbox"/> MINIMIZE HARMFUL OR INEFFECTIVE INTERVENTIONS. <input type="checkbox"/> ASSURE APPROPRIATE LEVEL OF CARE. <input type="checkbox"/> ASSURE APPROPRIATE DURATION OF SERVICE FOR INTERVENTIONS. <input type="checkbox"/> ASSURE THAT RECOMMENDED MEDICAL PREREQUISITES HAVE BEEN MET. <input type="checkbox"/> ASSURE APPROPRIATE SITE OF TREATMENT OR SERVICE.
Effective Date:	11/1/2025

[POLICY RATIONALE](#)

[CODING INFORMATION](#)

[PRODUCT VARIATIONS](#)

[DEFINITIONS](#)

[REFERENCES](#)

[DESCRIPTION/BACKGROUND](#)

[DISCLAIMER](#)

[POLICY HISTORY](#)

I. POLICY

Assay testing for determining 5-fluorouracil area under the curve in order to adjust 5-fluorouracil (5-FU) dose for individuals with cancer is considered **investigational**.

Testing for genetic variants in dipyrimidine dehydrogenase (*DPYD*) or thymidylate synthase (*TYMS*) genes to guide 5-FU dosing and/or treatment choice in individuals with cancer is considered **investigational**.

There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with the above procedures.

Policy Guidelines

GENETICS NOMENCLATURE UPDATE

Human Genome Variation Society (HGVS) nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It is being implemented for genetic testing medical evidence review updates starting in 2017 (see Table PG1). HGVS nomenclature is recommended by HGVS, the Human Variome Project, and the Human Genome Organization (HUGO).

The American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP) standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology—“pathogenic,” “likely pathogenic,” “uncertain significance,” “likely benign,” and “benign”—to describe variants identified that cause Mendelian disorders.

Table PG1. Nomenclature to Report on Variants Found in DNA

Previous	Updated	Definition
----------	---------	------------

MEDICAL POLICY

POLICY TITLE	LABORATORY AND GENETIC TESTING FOR USE OF 5-FLUOROURACIL IN PATIENTS WITH CANCER
POLICY NUMBER	MP 2.354

Mutation	Disease-associated variant	Disease-associated change in the DNA sequence
	Variant	Change in the DNA sequence
	Familial variant	Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives

Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification

Variant Classification	Definition
Pathogenic	Disease-causing change in the DNA sequence
Likely pathogenic	Likely disease-causing change in the DNA sequence
Variant of uncertain significance	Change in DNA sequence with uncertain effects on disease
Likely benign	Likely benign change in the DNA sequence
Benign	Benign change in the DNA sequence

ACMG: American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

GENETIC COUNSELING

Experts recommend formal genetic counseling for patients who are at risk for inherited disorders and who wish to undergo genetic testing. Interpreting the results of genetic tests and understanding risk factors can be difficult for some patients; genetic counseling helps individuals understand the impact of genetic testing, including the possible effects the test results could have on the individual or their family members. It should be noted that genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing; further, genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

Cross-Reference:
NA

II. PRODUCT VARIATIONS

[TOP](#)

This policy is only applicable to certain programs and products administered by Capital Blue Cross and subject to benefit variations as discussed in Section VI. Please see additional information below.

FEP PPO - Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at:

<https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>

MEDICAL POLICY

POLICY TITLE	LABORATORY AND GENETIC TESTING FOR USE OF 5-FLUOROURACIL IN PATIENTS WITH CANCER
POLICY NUMBER	MP 2.354

III. DESCRIPTION/BACKGROUND

[TOP](#)

5-FLUOROURACIL

The agent 5-fluorouracil (5-FU) is a widely used antineoplastic chemotherapy drug that targets thymidylate synthase (TYMS) enzyme, which is involved in DNA production. 5-FU has been used for many years to treat solid tumors (e.g., colon and rectal cancer, head and neck cancer). In general, the incidence of grade 3 or 4 toxicity (mainly neutropenia, diarrhea, mucositis, and hand-foot syndrome) increases with higher systemic exposure to 5-FU. Several studies also have reported statistically significant positive associations between 5-FU exposure and tumor response. In current practice, however, 5-FU dose is reduced when symptoms of severe toxicity appear but is seldom increased to promote efficacy.

Based on known 5-FU pharmacology, it is possible to determine a sampling scheme for area under the curve (AUC) determination and to optimize an AUC target and dose-adjustment algorithm for a particular 5-FU chemotherapy regimen and patient population. For each AUC value or range, the algorithm defines the dose adjustment during the next chemotherapy cycle most likely to achieve the target AUC without overshooting and causing severe toxicity.

In clinical research studies, 5-FU blood plasma levels most recently have been determined by high-performance liquid chromatography or liquid chromatography coupled with tandem mass spectrometry. Both methods require expertise to develop an in-house assay and may be less amenable to routine clinical laboratory settings.

REGULATORY STATUS

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests (LDTs) must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Assay testing for 5-fluorouracil blood plasma concentrations and genetic testing for variants in *DPYD* and *TYMS* for predicting risk of 5-fluorouracil toxicity and chemotherapeutic response (ARUP Laboratories) are available under the auspices of CLIA. Laboratories that offer LDTs must be licensed by CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test. The My5-FU assay is no longer marketed by Saladax Biomedical or Myriad Genetics in the United States. It is possible that therapeutic drug monitoring for 5-FU is available at a given institution as an in-house assay.

IV. RATIONALE

[TOP](#)

SUMMARY OF EVIDENCE

For individuals who have cancer for whom treatment with 5-FU is indicated who receive laboratory assays to determine 5-FU area under the curve, the evidence includes RCTs, observational studies, and systematic reviews. Relevant outcomes are overall survival, disease-specific survival, test accuracy and validity, and treatment-related morbidity. Several analyses of patients with colorectal cancer have evaluated clinical validity. Two studies found that the rate of severe toxicity was significantly lower in patients with metastatic colorectal cancer who received dosing using pharmacokinetic monitoring versus body surface area; however, progression free

MEDICAL POLICY

POLICY TITLE	LABORATORY AND GENETIC TESTING FOR USE OF 5-FLUOROURACIL IN PATIENTS WITH CANCER
POLICY NUMBER	MP 2.354

survival was not significantly different between groups. Most RCTs and nonrandomized studies comparing health outcomes were either single-center or did not use chemotherapy regimens used in current clinical practice. A systematic review of the available literature found a significantly higher response rate with body surface area-based monitoring and no significant difference in toxicity. Most data derived from observational studies and the RCTs were conducted in the 1980s when different chemotherapy protocols were used. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have cancer for whom treatment with 5-FU is indicated who receive genetic testing for variants (e.g., in DPYD and TYMS) affecting 5-FU metabolism, the evidence includes observational studies and systematic reviews. Relevant outcomes are overall survival, disease-specific survival, test accuracy and validity, and treatment-related morbidity. A TEC Assessment (2010) concluded that DPYD and TYMS variant testing had poor prognostic capacity to identify patients likely to experience severe 5-FU toxicity. Since the publication of that Assessment, no prospective trials comparing the efficacy and toxicity outcomes in patients who did and did not undergo pretreatment DPYD and/or TYMS testing have been published. Three prospective observational studies used a historical control group and 1 also used a matched-pairs analysis to compare outcomes in patients who received genotype-based dosing to those who received standard dosing. No differences in overall survival, progression-free survival, or tumor progression were observed. Risk of serious toxicity was higher in DPYD allele carriers who received genotype-based dosing compared to wild-type patients but lower when compared to historical controls who were carriers but received standard dosing. The evidence is limited by retrospective data collection, use of historical control groups, small sample sizes, and missing data. The evidence is insufficient to determine the effects of the technology on health outcomes

V. DEFINITIONS

[TOP](#)

NA

VI. DISCLAIMER

[TOP](#)

Capital Blue Cross' medical policies are used to determine coverage for specific medical technologies, procedures, equipment, and services. These medical policies do not constitute medical advice and are subject to change as required by law or applicable clinical evidence from independent treatment guidelines. Treating providers are solely responsible for medical advice and treatment of members. These policies are not a guarantee of coverage or payment. Payment of claims is subject to a determination regarding the member's benefit program and eligibility on the date of service, and a determination that the services are medically necessary and appropriate. Final processing of a claim is based upon the terms of contract that applies to the members' benefit program, including benefit limitations and exclusions. If a provider or a member has a question concerning this medical policy, please contact Capital Blue Cross' Provider Services or Member Services.

MEDICAL POLICY

POLICY TITLE	LABORATORY AND GENETIC TESTING FOR USE OF 5-FLUOROURACIL IN PATIENTS WITH CANCER
POLICY NUMBER	MP 2.354

VII. CODING INFORMATION

[TOP](#)

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Investigational; therefore, not covered:

Procedure Codes							
81232	81346						

VIII. REFERENCES

[TOP](#)

1. Kline CL, Schiccitano A, Zhu J, et al. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens. *Clin Colorectal Cancer*. Jun 2014; 13(2):119-126. PMID 24461492
2. Saam J, Critchfield GC, Hamilton SA, et al. Body surface area-based dosing of 5-fluorouracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens. *Clin Colorectal Cancer*. Sep 2011; 10(3):203-206. PMID 21855044
3. Gamelin E, Boisdron-Celle M, Delva R, et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. *J Clin Oncol*. Apr 1998; 16(4):1470-1478. PMID 9552054
4. Boisdron-Celle M, Craipeau C, Brienza S, et al. Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences. *Cancer Chemother Pharmacol*. Mar 2002; 49(3):235-243. PMID 11935216
5. Wilhelm M, Mueller L, Miller MC, et al. Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice. *Clin Colorectal Cancer*. 2016 Dec; 15(4). PMID 27256667
6. Milano G, Etienne MC, Renee N, et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. *J Clin Oncol*. Jun 1994; 12(6):1291-1295. PMID 8201391
7. Santini J, Milano G, Thyss A, et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. *Br J Cancer*. Feb 1989; 59(2):287-290. PMID 2930694
8. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. *Cancer*. Feb 1 1996; 77(3):441-451. PMID 8630950
9. Gamelin E, Delva R, Jacob J, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter

MEDICAL POLICY

POLICY TITLE	LABORATORY AND GENETIC TESTING FOR USE OF 5-FLUOROURACIL IN PATIENTS WITH CANCER
POLICY NUMBER	MP 2.354

- randomized trial of patients with metastatic colorectal cancer. J Clin Oncol. May 1 2008; 26(13):2099-2105. PMID 18445839*
10. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. *J Clin Oncol. Jul 1 2009; 27(19):3109-3116. PMID 19451431*
 11. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. *J Clin Oncol. Aug 2000; 18(16):2938-2947. PMID 10944126*
 12. Fety R, Rolland F, Barberi-Heyob M, et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5- fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. *Clin Cancer Res. Sep 1998; 4(9):2039-2045. PMID 9748117*
 13. Yang R, Zhang Y, Zhou H, et al. Individual 5-fluorouracil dose adjustment via pharmacokinetic monitoring versus conventional body-area-surface method: a meta-analysis. *Ther Drug Monit. Feb 2016; 38(1):79-86. PMID 26309030*
 14. Grem JL. 5-Fluorouracil and its biomodulation in the management of colorectal cancer. In: Saltz LB, ed. *Colorectal Cancer: Multimodality Management*. Totowa, NJ: Humana Press; 2002.
 15. Caudle KE, Thorn CF, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. *Clin Pharmacol Ther. Dec 2013; 94(6):640-645. PMID 23988873*
 16. ARUP Laboratories. 5-Fluorouracil Toxicity and Chemotherapeutic Response Panel. 2016;
 17. Li Q, Liu Y, Zhang HM, et al. Influence of DPYD genetic polymorphisms on 5-fluorouracil toxicities in patients with colorectal cancer: a meta-analysis. *Gastroenterol Res Pract. Jan 2014; 2014:827989. PMID 25614737*
 18. Rosmarin D, Palles C, Church D, et al. Genetic markers of toxicity from capecitabine and other fluorouracil- based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. *J Clin Oncol. Apr 1 2014; 32(10):1031-1039. PMID 24590654*
 19. Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. *J Clin Oncol. May 1 2008; 26(13):2131-2138. PMID 18299612*
 20. Boige V, Vincent M, Alexandre P, et al. DPYD genotyping to predict adverse events following treatment with fluorouracil-based adjuvant chemotherapy in patients with stage III colon cancer: a secondary analysis of the PETACC-8 Randomized Clinical Trial. *JAMA Oncol. Jan 21 2016; 2(5):655-662. PMID 26794347*
 21. Vazquez C, Orlova M, Angriman F, et al. Prediction of severe toxicity in adult patients under treatment with 5- fluorouracil: a prospective cohort study. *Anticancer Drugs. Oct 2017; 28(9):1039-1046. PMID 28723867*
 22. Wang YC, Xue HP, Wang ZH, et al. An integrated analysis of the association between Ts gene polymorphisms and clinical outcome in gastric and colorectal cancer patients treated with 5-FU-based regimens. *Mol Biol Rep. Jul 2013; 40(7):4637-4644. PMID 23645036*
 23. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). *Pharmacogenetic Testing to Predict Serious Toxicity From 5-Fluorouracil (5-FU) for Patients Administered 5-FU-Based Chemotherapy for Cancer. TEC Assessments. 2010; 24: Tab 13.*

MEDICAL POLICY

POLICY TITLE	LABORATORY AND GENETIC TESTING FOR USE OF 5-FLUOROURACIL IN PATIENTS WITH CANCER
POLICY NUMBER	MP 2.354

24. Deenen MJ, Meulendijks D, Cats A, et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. *J Clin Oncol.* Jan 20 2016; 34(3):227-234. PMID 26573078
25. Henricks, LL, van Merendonk, LL, Meulendijks, DD, Deenen, MM, Beijnen, JJ, de Boer, AA, Cats, AA, Schellens, JJ. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis. *Int. J. Cancer,* 2018 Nov 30; 144(9). PMID 30485432
26. Henricks, LL, Lunenburg, CC, de Man, FF, Meulendijks, DD, Frederix, GG, Kienhuis, EE, Creemers, GG, Baars, AA, Dezentj, VV, Imholz, AA, Jeurissen, FF, Portielje, JJ, Jansen, RR, Hamberg, PP, Ten Tije, AA, Droogendijk, HH, Koopman, MM, Nieboer, PP, van de Poel, MM, Mandigers, CC, Rosing, HH, Beijnen, JJ, Werkhoven, EE, van Kuilenburg, AA, van Schaik, RR, Mathijssen, RR, Swen, JJ, Gelderblom, HH, Cats, AA, Guchelaar, HH, Schellens, JJ. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. *Lancet Oncol.,* 2018 Oct 24; 19(11). PMID 30348537
27. Goff LW, Thakkar N, Du L, et al. Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers. *PLoS One.* Sep 2014; 9(9):e107424. PMID 25232828
28. Magnani E, Farnetti E, Nicoli D, et al. Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule. *Intern Emerg Med.* Aug 2013; 8(5):417-423. PMID 23585145
29. Cremolini, CC, Del Re, MM, Antoniotti, CC, Lonardi, SS, Bergamo, FF, Loupakis, FF, Borelli, BB, Marmorino, FF, Citi, VV, Cortesi, EE, Moretto, RR, Ronzoni, MM, Tomasello, GG, Zaniboni, AA, Racca, PP, Buonadonna, AA, Allegrini, GG, Ricci, VV, Di Donato, SS, Zagonel, VV, Boni, LL, Falcone, AA, Danesi, RR. *NA. Oncotarget,* 2018 Mar 1; 9(8). PMID 29487697
30. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 3.2024.*
31. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. Version 2. 2024..*
32. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3.2024.*
33. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. Version 2.2024.*
34. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 2.2024.*
35. Beumer JH, Chu E, Allegra C, et al. *Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. Clin. Pharmacol. Ther.* 2019 Mar; 105(3). PMID 29923599
36. Amstutz U, Henricks LM, Offer SM, et al. *Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther.* Feb 2018; 103(2):210-216. PMID 29152729

MEDICAL POLICY

POLICY TITLE	LABORATORY AND GENETIC TESTING FOR USE OF 5-FLUOROURACIL IN PATIENTS WITH CANCER
POLICY NUMBER	MP 2.354

37. National Institute for Health and Care Excellence (NICE). Fluorouracil chemotherapy: The My5-FU assay for guiding dose adjustment [DG16]. 2014

IX. POLICY HISTORY

[Top](#)

MP 2.354	02/04/2020 Consensus Review. No change to policy statements. References updated; coding reviewed.
	01/14/2021 Consensus Review. No change to policy statements. References updated.
	04/15/2022 Consensus Review. No change to policy statements. Added NCCN statement. Updated FEP, rationale, and references. No coding changes.
	04/20/2023 Consensus Review. "My 5-fluorouracil™" was removed from the policy statement because this test is no longer commercially available in the U.S. Minor editorial refinements to policy statements; intent unchanged. Updated regulatory status, and references. No coding changes.
	06/19/2024 Consensus Review. No changes to policy statement. References updated. Coding reviewed, no changes.
	11/19/2024 Administrative Update. Removed NCCN statement.
	07/11/2025 Consensus Review. No changes to policy statement. Coding reviewed, no changes. Removed Codes: S3722 & 84999
	09/24/2025 Administrative Update. Removed Benefit Variations Section and updated Disclaimer.

[Top](#)

Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company®, and Keystone Health Plan® Central. Independent licensees of the Blue Cross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.